NCT03028766View on ClinicalTrials.gov

WEE1 Inhibitor with Cisplatin and Radiotherapy: a Trial in Head and Neck Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

June 22, 2017

Primary Completion Date

October 31, 2019

Study Completion Date

February 3, 2021

Conditions
Hypopharynx Squamous Cell CarcinomaOral Cavity Squamous Cell CarcinomaLarynx Cancer
Interventions
DRUG

AZD1775

AZD1775 is a potent, selective small molecule inhibitor of WEE1

DRUG

Cisplatin

Chemotherapy drug

RADIATION

Radiotherapy

Intensity Modulated Radiotherapy

Trial Locations (6)

B15 2TH

University Hospital Birmingham Nhs Foundation Trust, Birmingham

G12 0YN

Beatson West of Scotland Cancer Centre, Glasgow

LS9 7TF

St. James' University Hospital, Leeds Teaching Hospital NHS Trust, Leeds

SW3 6JJ

The Royal Marsden Hospital, London

W1T 7HA

University College London Hospitals, London

CH63 4JY

Clatterbridge Cancer Centre, Metropolitan Borough of Wirral

Sponsors
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

collaborator

Cancer Research UK

OTHER

lead

University of Birmingham

OTHER